secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023202
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program
-------------------------------------------------------------------

- Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.
- Cash $752.2M as of Sep 30, 2022; expected runway into 2026.
- XEN1101 Phase 3 trials X-TOLE2, X-TOLE3 (FOS) and X-ACKT (PGTCS) initiated.
- X-NOVA MDD Phase 2 topline data expected Q3 2023.
- R&D expenses $29.4M, up 56% YoY, driven by XEN1101 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/0000950170-22-023202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017022023202/xene-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer